People with multiple sclerosis and obesity can achieve substantial weight loss, leading to improved mobility and quality of life, with a specially designed program, new trial results suggest.
Tirzepatide offers another "tool in the toolbox" as study demonstrates 20% weight loss attained in people with obesity without diabetes after a 12-week lifestyle intervention.
Final data from SURMOUNT-3 (tirzepatide), real-world experience with the latest antiobesity drugs, a standards-of-care document in the works, and more will be featured at Obesity Week 2023 in Dallas.